Shots:

• The P-III ASCEMBL study involves assessing of Asciminib (ABL001) vs bosutinib in patients with Ph+ CML-CP- prior treated with two or more TKIs
• The study met its 1EPs of superiority in major molecular response (MMR) rate @24wks.
• Asciminib (ABL001) is an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP)- being evaluated in multiple clinical studies addressing the needs of CML patients. The US FDA has granted FT designation for the therapy

­ Ref: Novartis | Image: Novartis